Index

Page numbers in italics represent figures, those in bold represent tables.

abciximab 240
abscess  
aortic root 340
myocardial 355
peri-aortic 349
activated partial thromboplastin time 86
activator protein-1 10
acute coronary syndromes 234–51
clinical presentation 237
definition 235–6, 236
diagnosis 236–7, 244–5
examination 236, 238
history 236
hypertension in 416–17
investigation 236, 238
low risk 243
management  
  factors complicating 243
  following surgical revascularization 247–8
  post-percutaneous intervention 247
  post-resuscitation 247
pathophysiology 235
peri-operative 245
risk scores 238, 238
risk stratification 237
standard management 238–43, 239
acute kidney injury 201–4
contrast-induced nephropathy 202–4, 203
Risk-Injury-Failure-Loss-End-stage (RIFLE) classification 201
acute lung injury 204–5
and pulmonary hypertension 371
transfusion-related (TRALI) 86, 204
acute respiratory distress syndrome 204
computed tomography 73
Addisonian crisis 445
adenosine 309
adenosine triphosphate (ATP) 104
adenylate cyclase 104
adhesion molecules 13, 349
adrenal failure/insufficiency 77, 445–7, 446
causes 446
relative 445–7
adrenaline 30, 107, 107
adrenocorticotrophic hormone (ACTH) 77
adult congenital heart disease (ACHD) 167–91, 290–301
anaesthesia 174–9
analgesia 176
elective cardioversion 176–7
elective electrophysiological interventions 177–8
emergency electrophysiological interventions 177
induction 175
intubated and sedated patients 176
maintenance 175
paralysis 176
patient monitoring in intensive care unit 175
aortic coarctation 293, 294
post-operative intensive care unit admission 183, 184
aortic valve and root disease 182–3, 183
arrhythmias 179, 303–12
bradycardia 309–10
management 293, 304
post-acute treatment care 310–11
tachycardia 304–6, 306, 308–9
atrial septal defect 293, 295
post-operative intensive care unit admission 183–5, 184, 185
atrio-ventricular septal defect 185, 185
classification of 169
cyanotic 170
adult congenital heart disease (ACHD) (cont’d)
double outlet right ventricle 298
Ebstein’s anomaly 172, 297, 297
post-operative intensive care unit admission 186
endocarditis risk 180–1, 350
failing morphological right ventricle 170–2, 172
Fallot’s tetralogy 295–7
post-operative intensive care unit admission 185–6, 186
Fontan circulation 173, 298–9, 299
anaesthesia 178–9
post-operative intensive care unit admission 188–9
and haemoptysis 180
heart failure 179–80
intensive care unit admission
medical indications 179–81
post-operative 181–9, 181, 182
outcomes of surgery 181
pathologies associated with 171
pre-operative risk assessment 291–3, 291, 292
arrhythmias 293
conduit replacement 292, 292
cyanosis 293
redo sternotomy 291–2
pregnancy 429
principles of management 168–70, 169
pulmonary hypertension, anaesthesia 178
sub-aortic stenosis 295
surgical procedures 292
systemic-pulmonary shunt 187–8
anaesthesia 178
transposition of great arteries 187, 298
congenitally corrected 172, 298
intensive care unit admissions 182, 187
univentricular heart 173–4, 173, 174
ventricular septal defect 295
adult respiratory distress syndrome 221
advanced life support 26
afterload 102–3
airway
post-resuscitation 34
resuscitation 25–7
albumins 222
alpha methylidopa 111
alpha-adrenoceptor agonists 110–11
alpha-adrenoceptor blockers 113
aminophylline 203
amiodarone 30, 130–1
atrial fibrillation 308
amniotic fluid embolism 428
amyloidosis 262, 262
anaesthesia
adult congenital heart disease 174–9
analgesia 176
elective cardioversion 176–7
emergency electrophysiological interventions 177
Fontan circulation 178–9
induction 175
intubated and sedated patients 176
maintenance 175
paralysis 176
patient monitoring in intensive care 175
pulmonary hypertension 178
systemic-pulmonary shunts 178
aortic dissection surgery 394–5
analgesia
adult congenital heart disease patients 176
hypertensive emergencies 418
anaphylactic shock 10
angiotensin converting enzyme inhibitors inhibitors 111–12
cardiogenic shock 258
hypertensive emergencies 418, 421
angiotensin II 104, 104
angiotensin II receptor antagonists 113
anti-arrhythmics 30–1
anti-neutrophil cytoplasmic antibody 436
anti-nuclear antibody 436
anti-platelet drugs 239, 242
antibiotics
endocarditis 351–2
post-transplantation 286
anticoagulation, patients with prosthetic valves 88–9
antifibrinolytics 87–8, 95
antihypertensives 418, 419–21
see also individual drugs/drug types
antithrombin 15
aorta
intra-mural haematoma 397
penetrating atherosclerotic ulcer 397
vasculitis 435
aortic coarctation 293, 294
intensive care unit admissions 182, 183, 184
aortic dissection 383–98
aetiology 384, 385
classification 386, 387, 387
clinical presentation 386–7
differential diagnosis 388
histology 384–5
hypertension in 388–9, 417–18
investigations 389–92
  aortography 391
  chest X-ray 389
  coronary angiography 391
  computed tomography 389
  echocardiography 389–90, 390
  intravascular ultrasound 391–2
  laboratory 389
  magnetic resonance imaging 390–1
late complications 396–7
malperfusion phenomena 386
management 392–5
  medical 392
  surgical 392–5, 393
outcomes 396, 396
physical signs 388–9
pregnancy 427
propagation 385–6
symptoms 387–8
type A
  outcome 396, 396
  surgery 392–3, 393
type B
  outcome 396
  surgery 393–4
aortic injury 405–7
diagnosis 406
management 406–7, 407
outcome 407
aortic regurgitation 325, 337–40
clinical features 337–8, 338
diagnosis 337
  echocardiography 338, 339, 340
indications for intensive care unit
  admission 337–40
management 339–40
moderate 340
pre-operative coronary arteriography 338–9
as incidental finding 336–7
indications for intensive care unit admission 333
with left ventricular disease 331, 332
management 335–6
  supportive therapy 336
aortic valve disease
  intensive care unit admissions 182, 182, 183
  regurgitation see aortic regurgitation
  stenosis see aortic stenosis
aortic valve replacement (AVR) 341–3
bioprosthetic malfunction 342–3
mechanical malfunction 341, 342
patients with previous aortic valve replacement 341
post-operative management 343–4
aortography 391
AP214 203
APACHE II score 179
aprotinin 95, 195
arginine vasopressin
  cardiac donors 283
severe sepsis 227
arrhythmias 120–33
  adult congenital heart disease 179, 303–12
  bradycardia 309–10
  management 293, 304
  post-acute treatment care 310–11
  tachycardia 304–6, 306, 308–9
asystole 29–30, 29
atrial
  fibrillation/flutter 126, 128–9
  incidence 121, 122
  morbidity 123–4
  cardiac arrest 27–30
  diagnosis 67
  electrocardiogram 63–4, 64
  incidence 121–3, 122, 122, 123
  management 127–31
    pharmacotherapy for cardiac surgery 129–30
  modifiable risk factors 124–7
  arterial oxygen/carbon dioxide tensions 125
  central venous cannulae 124–5
  magnesium 125–6
  potassium 126–7
  morbidity 123–4
  peri-arrest 31, 32
  post-myocardial infarction 246
  post-transplantation 280–1
pulseless electrical activity 29–30, 29
ventricular
Index

fibrillation 27–9, 28
incidence 121
moridity 124
tachycardia 27–9, 28
arterial carbon dioxide tension, and risk of arrhythmias 125
arterial oxygen saturation 228
arterial oxygen tension, and risk of arrhythmias 125
arterial switch 292
aspirin 239, 240, 242
adverse reactions 246
asystole 29–30, 29
atenolol 107, 113–14
atrial arrhythmias
  fibrillation 88, 126, 128–9
  flutter 126, 128–9
  incidence 121, 122
  morbitity 123–4
atrial septal defect 293, 295
intensive care unit admissions 183–5, 184
ostium secundum 182, 293
sinus venosus 182, 293, 295
atrio-ventricular septal defect, intensive care unit admissions 182, 185
atrioventricular block 307
atopine 31
autologous donation, pre-operative 9
automatic implantable cardioverter defibrillator 65
autoregulation 103

B-type natriuretic peptide 375
Band, David 454
baroreceptors 103, 105
baroreceptor reflexes 105
Behçet’s disease 436, 437, 438
benzodiazepines, hypertensive emergencies 418
beta-adrenoceptor agonists 131
beta-adrenoceptor blockers 113–14
cardiogenic shock 258
hypertensive emergencies 419
bisoprolol 113–14
Blalock-Taussig shunt 187–8, 292
bleeding
  centile chart 85
  management 83–8, 84
  antifibrinolytic drugs 87–8
  cryoprecipitate 86
  fresh frozen plasma 86
  platelets 84, 86
  recombinant factor Vlla 86–7
  red cells 84
  mechanical assist devices 148
Blood Conservation using
  Antifibrinolytics in a Randomized Trial (BART) study 95
blood pressure 43, 44
monitoring 44–6
see also hypertension
blood sparing techniques 94–6
peri-operative 95–6
acute normovolaemic haemodilution 95
antifibrinolytic agents 95
cell salvage 96
post-operative 96
preoperative interventions 94–5
drug management 94–5
haematinic therapy 94
pre-operative autologous donation 95
blood transfusion, risks of 84
blue kidneys 170
blunt cardiac trauma 401, 403–5
diagnosis 403–4
management 404–5, 405
outcome 405
Bohr equation 206
bosentan 115
  pulmonary hypertension 377–8
bradycardia
  adult congenital heart disease 309–10
  sinus 307
  breathing 27
  buffers 31
C-reactive protein 258, 360
calcium 31
calcium antagonists
  hypertensive emergencies 418
  see also individual drugs
calcium channels 104
calcium salts 110
calcium sensitisers 109
calmodulin 104
Canadian Cardiovascular Society Index 156
Candida albicans 349
carcinoid tumours 78
cardiac arrest
  imminent 24
  in pregnancy 425
cardiac catheterisation 310
cardiac enzymes 13  
blunt cardiac injury 403–4  
cardiac failure, chronic decompensated 143–4  
cardiac index  
septic shock 220  
suboptimal 158  
cardiac magnetic resonance 74–5  
cardiac output 44, 47, 101  
low 66  
echocardiography 69  
measurement of 455–6, 461  
post-surgery 66–7  
septic shock 220  
cardiac plexus 102  
cardiac rhythm 27  
disturbances of see arrhythmias  
cardiac rupture 246  
cardiac tamponade 6–7, 29, 198, 198  
cardiogenic shock 274  
and haemodynamic instability 67  
post-transplantation 283–4  
cardiac transplantation  
cardiogenic shock 272–3  
graft failure 281  
peri-operative care 279–87, 280  
antiotics 286  
haemodynamic management 281–4  
immunosuppression 284–6, 285  
survival 280  
cardiac trauma 401–20  
aortic injury 405–7  
diagnosis 406  
management 406–7, 407  
outocme 407  
blunt 401, 403–5  
diagnosis 403–4  
management 404–5, 405  
outcome 405  
emergency care 402–3  
investigation 403  
penetrating 402, 407–9  
investigation 407–8  
management 408, 409  
outcome 409  
signs of 402  
cardiogenic shock 2, 6, 52, 256–74  
cardiac tamponade 274  
causes and epidemiology 256–8, 257  
clinical features and diagnosis 259–63  
echocardiography 260–2, 262  
invasive haemodynamic monitoring 262–3  
diastolic disease 273  
management 263–73  
inotropic and vasopressor agents 270–2  
intra-aortic counterpulsation 263–7, 264, 265  
left ventricular assist devices and transplantation 272–3  
pacing 272  
revascularisation 267–70, 268, 270  
ventilation 272  
and myocardial infarction 143, 256–7, 260–1  
non-ischaemic 261–2  
pathophysiology 258–9  
right ventricular failure 273  
cardiomyopathy 144  
peripartum 429  
cardiopulmonary ratio 71  
cardiovascular interventions, high-risk  
surgical patients 157–61, 158, 160, 161  
cardiovascular investigation 62–80  
biochemistry 76–8  
cardiac magnetic resonance and nuclear medicine 74–5  
electrocardiogram 63–5  
fluid responsiveness 67  
haemodynamic instability 65–7  
invasive catheterisation procedures 72–4, 74, 75  
permanent pacemaker implantation 65  
radiography 70–2, 73  
ultrasound 67–70, 69, 70  
cardiovascular monitoring 42–57, 49  
response to therapy 52–6  
passive leg raising 55–6  
positive pressure ventilated patients 54–5, 55  
spontaneous breathing 55  
volume challenge 53–4  
single variables 44–52, 45  
arterial blood pressure 44–6  
central venous pressure 46–7  
grouping of 52  
pulmonary artery catheter 47–8  
pulmonary artery occlusion pressure 48–52, 49, 50  
cardiovascular physiology 101–3  
haemodynamic parameters 101–3  
regulation of 103–6  
cardioversion 129  
elective in adult congenital heart disease patients 176–7
CASINO trial 271
catecholamines 106–7, 107
see also individual compounds
cathepsin G 195
catheterisation 72–4, 74, 75
left heart 72–3, 74
right heart 73, 75
ceftriaxone 286
cell salvage 96
central nervous system dysfunction 209
central venous cannulae, risk of arrhythmias 124–5
central venous oxygen saturation 48, 222
central venous pressure 44, 462
monitoring 46–7
centrifugal pumps 141
cerebral function, post-arrest 35
cerebral ischaemia 209
chemokines 12–13
chemoreceptors 103
chest trauma, computed tomography 73
chest X-ray 70–1
aortic dissection 389
aortic injury 406
penetrating cardiac trauma 407
chronic obstructive pulmonary disease, and pulmonary hypertension 371–2
chronotropic incompetence 310
Churg-Strauss disease 437, 438
chyle 206
circulation 27
post-resuscitation 34
cisaprost 114
clonidine 111
clopidogrel 239, 240, 242
coa coagulation abnormalities 14–15
coa coagulopathy 280
coarctation of aorta see aortic coarctation
colloids 5, 222
common arterial trunk 173
compartment syndrome 200–1, 211–12
complement system 16–17, 258
complications 193–212
cardiovascular dysfunction 196–201
compartment syndrome 200–1
myocardial 196–7
pericardial collections and tamponade 197–200
peripheral ischaemia 201
tight pericardium 200
gastrointestinal dysfunction 207–8
liver dysfunction 207
pancreatitis 208
splanchic ischaemia 207–8
neurological dysfunction 208–9
central nervous system dysfunction 209
spinal cord injury 208
renal dysfunction 201–4
contrast-induced nephropathy 202–4, 203
Risk-Injury-Failure-Loss-End-stage (RIFLE) classification 201
respiratory dysfunction 204–7
acute lung injury 204–5
phrenic nerve dysfunction 207
pleural effusions 205–7
pulmonary atelectasis 205
sites of 194
sternal wounds 210
systemic disorders 194–6
corticosteroid insufficiency 195–6
hyperglycaemia 196
inflammation 194–5
computed tomography
aortic dissection 390, 391
aortic injury 406
penetrating cardiac trauma 408
pulmonary angiography 71–2
pulmonary embolism 73
thorax 72, 73
computed tomography angiography, pulmonary hypertension 374–5, 375
conduit replacement 292, 292
contrast-induced nephropathy 202–4, 203
coronary angiography 79
aortic dissection 391
indications 74
coronary arteriography, mitral regurgitation 338–9
coronary artery bypass graft arrhythmias 122
and graft failure 247–8
complications 247–8
coronary artery vasculitis 435
coronary steal 420
corticosteroids insufficiency, critical illness-related 195–6
severe sepsis 227
corticotrophin-releasing hormone 77
CORTICUS study 228, 446
cortisol 77
Cowell, Terry 457
Coxiella burnetii 352
creatine kinase
  aortic dissection 389
  blunt cardiac injury 403–4
critical care calling criteria 24
critical illness related corticosteroid insufficiency (CIRCI) 445
cryoprecipitate 86
crystalloids 5, 222
computed tomography see computed tomography
cyanosis
  adult congenital heart disease 170, 293
echocardiography 69
cyclic AMP 104
cyclic GMP 104
cyclophosphamide 439
cyclosporin 285
cystic medial necrosis 385
cytokines 11–12, 12
defibrillation 28, 28
delirium 209
Detsky score 156
dexmedetomidine 111
dextrose 222
diabetic ketoacidosis 442
diabetic patients 443–4
diacylglycerate 104
diastolic disease, cardiogenic shock 273
diazoxyde 113
digitalis glycosides 109
digoxin 109, 128
toxicity 31
3,4-dihydroxy-L-phenylalanine (L-DOPA) 107
diltiazem 309
  hypertensive emergencies 419
disseminated intravascular coagulation 15
distributive shock 2, 52
  do not attempt resuscitation (DNAR) orders 35–6
DO₂, suboptimal 158
dobutamine 107, 108
  cardiogenic shock 271
  severe sepsis 226
L-DOPA (3,4-dihydroxy-L-phenylalanine) 107
dopamine 107–8, 107, 203
  cardiogenic shock 271
  severe sepsis 224, 225
dopamine agonists 112
dopexamine 107, 108
  severe sepsis 226
Doppler echocardiography
  aortic stenosis 225
  mitral regurgitation 317, 317
double outlet right ventricle 298
Dressler’s syndrome 197
drotrecogin alfa 195
  severe sepsis 228
Early Warning Scores 24
Ebstein’s anomaly 172, 297, 297
  intensive care unit admissions 182, 186
electrocardiogram 43, 63–5
  aortic dissection 389
  arrhythmias 63–4, 64
  atrial tachycardia 306
  basic 63
  cardiac trauma, blunt 404
  myocardial ischaemia 63
  pericardial disease 64–5
  right ventricular dysfunction 64
echocardiography 68–9, 69
  aortic dissection 389–90, 390
  cardiac trauma
    blunt 404
    penetrating 408
  cardiogenic shock 260–2, 262
  as diagnostic tool 68, 69, 70
  Doppler
    aortic stenosis 225
    mitral regurgitation 317, 317
    as monitoring device 68
    peri-arrest 68
  pulmonary hypertension 69, 373–4, 373, 374
trans-oesophageal 177
  aortic injury 406
  aortic regurgitation 338, 339, 340
  aortic valve disease 330, 331
  infective endocarditis 353, 355
  left ventricular hypertrophy 332
  mitral regurgitation 317, 319
  pericardial effusion 198
  trans-thoracic 70, 80
  endocarditis 353, 355
Efficacy of Volume Substitution and Insulin Therapy in Severe Sepsis (VISEP) study 222
  eicosanoids 13, 14
  Eisenmenger’s syndrome
    anaesthesia 178
  intensive care unit admissions 182
electrocardiography  see electrocardiogram
electrophysiological interventions in adult congenital heart disease patients
elective 177–8
emergency 177
embolisation in endocarditis 357
embolism
amniotic fluid 428
pulmonary see pulmonary embolism
emergency revascularisation 248
empyema 206
encephalopathy
hypertension in 414
inflammatory 209
end-points 115
end-systolic pressure/volume relationship 102
endocarditis 347–62
adult congenital heart disease patients 180–1, 350
causative organisms 355–6, 356
complications 356–8, 358, 359
definition and incidence 348
diagnosis 352–5, 354
echocardiography 69, 353, 355
management 358–61, 360
medical 358–60
surgical 360–1, 360
native valve 350
non-bacterial thrombotic 349
outcome and prognosis 361
pathogenesis 348–50
post-operative management 361
prevention 351–2, 353
antibiotic prophylaxis 351–2
prosthetic valve 350
susceptible patients 350–1, 350
cardiac factors 350–1, 350
non-cardiac factors 351
endocrine disorders 76–8, 442–51
adrenal failure/insufficiency 77, 445–7, 446
carcinoid tumours 78
chromaffin tumours 78
hyperglycaemic states 442–3, 443
diabetic patients 443–4
stress-induced 444–5
thyroid dysfunction 76–7, 447–50, 448
hypothyroidism 448–9
myxoedema coma 449
thyroid crisis (‘storm’) 450
endocrine shock 2
endothelial dysfunction 14
endothelial injury 14
endothelin 1 104
endothelin receptor antagonists 115
pulmonary hypertension 377–8
enoxaparin 241, 242
enoximone 109
post-transplantation 282
severe sepsis 226
ephedrine 107, 110–11
erythrocytosis 170
erthyropoietin, recombinant 94
esmolol 113–14
hypertensive emergencies 419
ethical issues, resuscitation 35–6
European Resuscitation Council 23
Chain of Survival 23, 23
extra-corporeal membrane oxygenation 284
Fabry’s disease 262
factor VIIa, recombinant 86–7
factor VIII, activated 280
Fallot’s tetralogy 295–7
intensive care unit admissions 182, 185–6, 186
late primary repair 295–7, 296
pulmonary valve replacement 295
fenoldopam 112, 203
fibrin, absence of 384
fibronectin 349
fibrothorax 206
Fick principle 455
filling pressures
cardiogenic shock 261
increased, echocardiography 69
fludrocortisone, severe sepsis 227
fluid challenge 223
fluid loss, haemorrhagic shock 4
fluid responsiveness 67
fluid resuscitation 221–4
endpoints 223–4
type of fluid 222–3
Focused Assessment with Sonography for Trauma (FAST) scan 408
fondaparinux 241
Fontan circulation 173, 298–9, 299
anaesthesia 178–9
intensive care unit admissions 182, 188–9
Fontan procedure 292
force-velocity relationship 102
Frank-Starling law 101
fresh frozen plasma 6, 86
frusemide 203
G-protein coupled receptors 104
G-proteins 104
ganglion blockers 111
gastrointestinal dysfunction 207–8
  liver dysfunction 207
  pancreatitis 208
  splanchnic ischaemia 207–8
gelatins 222
giant-cell arteritis 436, 437
Glenn venous anastomosis 173
Global Registry of Acute Coronary Events (GRACE) score 238
Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-1) trial 265
glucagon 110
glucose 109–10
glyceryl trinitrate 112
  hypertensive emergencies 420
  pulmonary hypertension 377
  goal-directed therapy 159, 160
  Goldman risk index 155–6
  granulocyte-colony stimulating factor 12
  guanosine diphosphate (GDP) 104
  guanosine triphosphate (GTP) 104
  guanylate cyclase 104
HACEK organisms 356, 356
haematinic therapy 94
haematology 83–97
  anticoagulation, patients with prosthetic valves 88–9
  blood sparing techniques 94–6
  heparin-induced thrombocytopenia 89–91
  management of bleeding 83–8
  near patient testing 91, 93–4
  thromboprophylaxis 88
haemodilution, acute normovolaemic 95
haemodynamic impairment
  pharmacological management see pharmacological interventions rational approach 115–16, 116
  haemodynamic instability 65–7
  arrhythmias 67
  low cardiac output 66
  post-cardiac surgery 66–7
  haemodynamic monitoring 116, 454–63
  cardiogenic shock 262–3
  post-transplantation 281–4
  pericardial tamponade 283–4
  right ventricular function 281–3
  haemoptysis
    adult congenital heart disease patients 180
    right heart catheterisation 75
  haemorrhage see bleeding
  haemotherorax 206
  headache 170
  heart failure
    adult congenital heart disease patients 179–80
    causes 140
    endocarditis 356
    mechanical assist devices 139–51
  heart rate 43, 102
  heart transplantation 140
  heparin
    adverse reactions 246
    low molecular weight 88
    unfractionated 84
  heparin-induced thrombocytopenia 89–91, 92
    laboratory testing 89–90
    management 90–1
    pathophysiology 89, 90
  hepatitis, ischaemic 207
  high mobility group B1 12
  high output states 7–10
    anaphylactic shock 10
    neurogenic shock 10
    sepsis 7–10, 8, 9
  high-risk surgical patients 154–63
    identification of 154–7, 155, 156
    interventions 157–62
      cardiovascular 157–61, 158, 160, 161
      prevention of myocardial ischaemia 161–2
      risk of mortality 155
  hydralazine 113
  hypertensive emergencies 420
  hydrocortisone, severe sepsis 227
  hydroxyethyl starch 222
  hyperamylasaemia 208
  hyperglycaemic states 196, 442–3, 443
    diabetic patients 443–4
    stress-induced 444–5
  hyperkalaemia 29
  hyperlactataemia 207
  hyperosmolar non-ketotic state (HONK) 442
  hypertension
    aortic dissection 388–9, 417–18
    cardiac surgery and acute coronary syndromes 416–17, 417
    pregnancy 428
hypertensive crises 413–22
  causes 414
  definitions 414
  epidemiology 415
  management 418–21, 418
  beta-adrenoceptor blockers 419
  nitrates 420
  sodium nitroprusside 419–20
  organ dysfunction 414
  pathophysiology 415–16, 415
  presentation 416
  hyperviscosity syndrome 170
  hypoglycaemia 207
  hypokalemia 29
  arrhythmias 126–7
  hypomagnesaemia, arrhythmias 125–6
  hypoperfusion, cardiogenic shock 259
  hypotension, cardiogenic shock 259
  hypothalamic-pituitary-adrenal axis 77, 195
  hypothermia 29
  hypothyroidism 448–9
  hypovolaemia 29
  septic shock 220
  hypovolaemic shock 2, 3–6, 4, 52
  clinical features 4
  fluid loss 4
  management 4–6
  hypoxia 29
  right heart catheterisation 75

I5NP 203
  ibutilide 308
  iloprost 114, 115
  pulmonary hypertension 377
  immunosuppression 284–6, 285
  in-hospital resuscitation 24–7, 25
  airway 25–7
  breathing 27
  call for help 24
  circulation 27
  commencement of resuscitation 24–5, 26
  rhythm 27
  inamrinone 109
  infection, mechanical assist devices 148–9
  infective endocarditis see endocarditis
  inflammation
    pro-inflammatory response 13–17
    systemic 194–5
  inflammatory nitric oxide synthase 258
  inositol triphosphate 104
  inotropic agents
    cardiogenic shock 270–2
    severe sepsis 226–7
  insulin 109–10, 203
    hyperglycaemia 444
    systemic insulin resistance syndrome 443
  integrins 349
  intercellular adhesion molecules (ICAMs) 13
  interferon-γ 12
  interleukins 258
  interleukin-1β 12
  interleukin-1ra 12
  interleukin-4 12
  interleukin-6 12
  interleukin-10 12
  interleukin-12 12
  interleukin-13 12
  International Normalised Ratio (INR) 93
  intra-aortic balloon pump 336, 444
  intra-aortic counterpulsation 263–7
    in cardiogenic shock 265–6, 265
  contraindications and complications 266
  haemodynamic effects 263–4, 264
  patient management 266–7
  intra-mural haematoma 397
  intravascular volume 105
  iron replacement 94
  ischaemia
    cerebral 209
    myocardial see myocardial ischaemia
    peripheral 201
    splanchnic 207–8
  ischaemic heart disease
    mitral regurgitation 318–19
    in pregnancy 426–7
  ischaemic hepatitis 207
  isoproterenol 107, 108
  Janeway’s lesions 358
  Kawasaki’s disease 437, 439
  ketamine, induction of anaesthesia 175
  Korner, Peter 455
  labetolol 113
  hypertensive emergencies 418, 419
  lactate levels, in sepsis 229
  Lee index 156
  left atrial isomerism, intensive care unit admissions 182
left bundle branch block 235
left heart catheterisation 72–3, 74
left ventricular assist devices see mechanical assist devices
left ventricular dysfunction 246
  with mitral regurgitation 318–20, 319
left ventricular ejection fraction 258
left ventricular end-diastolic pressure 462
left ventricular hypertrophy 332
left ventricular outflow tract obstruction 185, 321, 322
left ventricular stroke work index, septic shock 220
Leriche syndrome 386
leukaemia inhibitory factor 12
leukotrienes 14
levosimendan 109, 247
  cardiogenic shock 271
  pulmonary hypertension 378
levosimendin, post-transplantation 282
LIDO trial 271
lidocaine 30, 309
lithium dilution cardiac output 262
liver dysfunction 207
low molecular weight heparin 88
low output states 2–7
  cardiogenic shock 6
  hypovolaemic shock 3–6, 4
  obstructive shock 6–7
lung
  transfusion-related acute injury (TRALI) 86, 204
ultrasound 70
macrophage migration factor 12
macrophages 15
magnesium sulphate 30–1, 308
  hypertensive emergencies 418
magnetic resonance imaging
  aortic dissection 390–1
  pulmonary hypertension 375–6
malperfusion 386
mannitol 203
marantic endocarditis 349
Marfan’s syndrome 384
Maze procedure 293
mean arterial pressure 45–6, 101, 103
  septic shock 220
mechanical assist devices 139–51
  acute management 147–50
  bleeding 148
  infection 148–9
  mechanical failure 149
  thromboembolism 147
cardiogenic shock 272–3
inductions 140, 143–4, 143
  acute myocardial infarction with cardiogenic shock 143
  decompensated chronic cardiac failure 143–4
  myocarditis and cardiomyopathy 144
  post-cardiac surgery 144
  methods of implantation 144–6
  percutaneous devices 145–6
  surgical connection 145, 145, 146
multi-organ failure and immunocompromise 149–50
physics of 140–2
  centrifugal pumps 141
  positive displacement pumps 141
  pulsatile vs non-pulsatile flow 141–2
post-transplantation 284
short-term vs long-term implantation 144
types of 142, 142
weaning and removal 150
mechanical circulatory support 65
Medical Emergency Team 24
metabolism, inflammatory response 16
metaraminol 107, 110, 175
methylprednisolone 285
metoprolol 113–14
  hypertensive emergencies 419
  microcirculation, inflammatory changes 14
milrinone 109
  cardiogenic shock 271
  post-transplantation 282
  pulmonary hypertension 378
  severe sepsis 226
minocycline 203
mitochondrial activity 15–16
mitogen-activated protein kinase 10
mitral regurgitation 246, 261, 316–20
diagnosis 316–18, 316
ischaemic 318–19
  left bundle branch block 319–20, 319
left ventricular disease associated with 318–20, 319
management 318
post-operative complications 321–4, 322
mitral stenosis 320
mitral valve disease 315–26
prosthetic valve 320–1, 322
regurgitation see mitral regurgitation
stenosis see mitral stenosis
mixed venous oxygen saturation 44, 47–8, 228
maximisation of 159
reduced 66
monocytes 15
magnetic resonance imaging see magnetic resonance imaging
multi-organ failure 149–50
muscle relaxants 176
Mustard procedure 172, 292
mycophenolate 285, 439
myocardial abscess 355
myocardial contractility 102
myocardial dysfunction 196–7
and cardiogenic shock 257
myocardial hibernation 258
myocardial infarction
and cardiogenic shock 143, 256–7, 260–1
clinical presentation 237
in critical care 243–7
definition 235–6, 236
diagnosis 235–6, 244–5
examination 236, 238
factors complicating treatment 243
haemodynamic instability after 246, 246
history 236
investigation 236, 238
management
following surgical revascularization 247–8
mechanical assist device 143
post-percutaneous intervention 247
post-resuscitation 247
markers of 76
non-ST segment elevation see non-ST segment elevation myocardial infarction
pathophysiology 235
peri-operative 196
prevention of 161–2
myocardial stunning 258
myocardial trauma, and cardiogenic shock 257
myocarditis 144, 436
myosin light chain 104
myosin light chain kinase 104
myxoedema coma 449
natriuretic peptides 76
near patient testing 91, 93–4, 93
nesiritide 203
cardiogenic shock 271
neurogenic shock 10
neurological dysfunction 208–9
central nervous system dysfunction 209
spinal cord injury 208
neutrophil-derived elastase 195
neutrophils 15
nitrates 112
hypertensive emergencies 418, 420
pulmonary hypertension 377
nitric oxide 103, 104, 114, 220
post-transplantation 284
pulmonary hypertension 376–7
nitric oxide donors 112
nitric oxide synthase 13
inflammatory 258
noradrenaline 104, 107, 110, 175
cardiogenic shock 271
severe sepsis 224–5, 225
NRMI-2 trial 265, 265
non-ST segment elevation myocardial infarction (NSTEMI)
definition 235
management 242–3
interventional/revascularisation strategies 242
pharmacological 242
nuclear factor-κB 10
nuclear medicine 74–5
obstructive shock 2, 6–7
oesophageal Doppler 157
oliguria, echocardiography 69
oncostatin M 12
optimisation, pre-surgery 157, 158
meta-analysis 161
organ failure 10–17
activation of pro-inflammatory system 13–17
gene induction and role of intermediaries 11–13, 12
inflammatory gene expression 10
intracellular signal pathways 10, 11
Osler’s nodes 358
ostium secundum defect 182, 293
oxygen 1
excessive consumption 158
pacemakers 65
pacing
bradycardia in adult congenital heart disease patients 310
cardiogenic shock 272
pancreatitis 208
paraplegia 208
parasympathetic nervous system 102
passive leg raising 55–6
pattern recognition receptors 8, 9
penetrating atherosclerotic ulcer 397
penetrating cardiac trauma 402, 407–9
investigation 407–8
management 408, 409
outcome 409
percutaneous coronary intervention 161
management after 247
peri-aortic abscess 349
pericardial disease, electrocardiogram 64–5
pericardial effusion 197–200
aetiology 197, 198
management 200
pathophysiology and diagnosis 197–9, 199
rate of fluid accumulation 199
pericarditis 435
pericardium, tight 200, 323
peripartum cardiomyopathy 429
peripheral ischaemia 201
phaeochromocytoma 78
pharmacological interventions 106–17
positive inotropes 106–10
vasoconstrictors 110–11
vasodilators 111–15
phentolamine, hypertensive emergencies 418, 420
phenylephrine 107, 110, 175
phosphatidyl inositol biphosphate 104
phosphodiesterase inhibitors 109, 115
post-transplantation 282–3
pulmonary hypertension 377
severe sepsis 226–7
phospholipase C 104
phrenic nerve dysfunction 207
platelet activating factor 14
platelets 14–15, 84, 86
pleural effusion 71, 205–7
computed tomography 73
drainage 206
Light’s criteria 205
pneumothorax
computed tomography 73
radiography 71
tension 7, 29
polyarteritis nodosum 437, 438
positive displacement pumps 141
positive inotropes 106–10
potassium 109–10
prazosin 113
pre-eclampsia 428
prednisolone 285
pregnancy 424–32
amniotic fluid embolism 428
aortic dissection 427
cardiac arrest 425
cardiovascular factors 425
congenital heart disease 429
delivery in critically ill patients 429–30
fetal issues 426
hypertension 428
ischaemic heart disease 426–7
peripartum cardiomyopathy 429
peripartum haemorrhage 426
pulmonary embolism 428
pulmonary hypertension 429
pulmonary oedema 427–8, 427
respiratory factors 425
thrombosis 425–6
preload 101–2
preload responsiveness
positive pressure ventilated patients 54–5, 55
spontaneous breathing 55
pro-inflammatory response 13–17
complement system 16–17
endothelium 14
metabolism 16
microcirculation 14
mitochondrial activity 15–16
monocytes/macrophages 15
neuro-endocrine system 16
neutrophils 15
platelets and coagulation system 14–15
procainamide 309
propofol, induction of anaesthesia 175
prostacyclin 103, 114, 220
post-transplantation 284
pulmonary hypertension 377
prostaglandins 14
prostaglandin E₂ 14
prosthetic valves
  anticoagulation 88–9
  endocarditis risk 350–1, 350
protein kinase 104
prothrombin complex concentrates 94
prothrombin time 86
Pseudomonas aeruginosa 355
pulmonary artery banding 292
pulmonary artery catheter 47–8, 51–2, 157, 374
pulmonary artery occlusion pressure
  44, 47, 48–52, 49, 50, 224
pulmonary atelectasis 205
pulmonary atresia 173
pulmonary capillary pressure 49–50, 50
pulmonary capillary wedge pressure 316
pulmonary embolism 7, 30
  computed tomography 73
  pregnancy 428
  and pulmonary hypertension 372
pulmonary endarterectomy 379, 379
pulmonary hypertension 172, 367–80
  anaesthesia 178
  aortic stenosis 343
  classification 368–9, 369
  definition 368
  diagnosis 373–6
  computed tomography
    angiography 374–5, 375
    echocardiography 69, 373–4, 373, 374
  pulmonary artery catheter 374
mitral valve surgery 323
pathophysiology 369–70
  acute lung injury 371
  acute pulmonary embolism 372
  chronic obstructive pulmonary disease 371–2
  chronic thromboembolic disease 372
  right ventricular failure 370–1, 371
  pregnancy 429
right heart catheterisation 75
treatment 376–9
  mechanical support and surgery 378–9, 379
  pharmacological 376–8
pulmonary oedema 50, 261
  pregnancy 427–8, 427
pulmonary stenosis, intensive care unit admissions 182
pulmonary valve replacement 295
pulmonary vascular resistance 50–1, 173, 462
pulmonary vasodilators 114–15
pulse contour cardiac output 157, 262
pulse oximetry 43
pulseless electrical activity 29–30, 29
PURSUIT score 238
radiography 70–2, 73
  anatomical aspects 71
  chest X-ray 70–1
  aortic dissection 389
  aortic injury 406
  penetrating cardiac trauma 407
  haemodynamics 71
  radionuclide scans, blunt cardiac trauma 404
Regulated upon Activation, Normal T-cells Expressed and Secreted (RANTES) 12–13
re-sternotomy 291–2
red cells 84
relapsing polychondritis 439
renal dysfunction 201–4
  contrast-induced nephropathy 202–4, 203
  Risk-Injury-Failure-Loss-End-stage (RIFLE) classification 201
renal failure, endocarditis 357
renin-angiotensin system,
  hypovolaemic shock 3
  renin-angiotensin-aldosterone system 104, 258
respiratory dysfunction 204–7
  acute lung injury 204–5
  phrenic nerve dysfunction 207
  pleural effusions 205–7
  pulmonary atelectasis 205
resuscitation 22–37
  advanced life support 26
  arrhythmias 27–30
  asystole and pulseless electrical activity 29–30, 29
  peri-arrest 31–2, 32, 33
  ventricular fibrillation/tachycardia 27–9, 28
drugs 30–1
  anti-arrhythmics 30–1
  vasopressors 30
endpoints 228–9, 229
ethical issues 35–6
European Resuscitation Council (ERC) Chain of Survival 23, 23
fluids 221–4
type of 222–3
in-hospital 24–7, 25
airway 25–7
breathing 27
call for help 24
circulation 27
commencement of resuscitation 24–5, 26
rhythm 27
management after 247
post-resuscitation care 34–5
recognition of imminent cardiac arrest 24
severe sepsis 228–9, 229
revascularisation
cardiogenic shock 267–70, 268, 270
emergency 248
management after 247–9
in-hospital 24–7, 25
airway 25–7
breathing 27
call for help 24
circulation 27
haemodynamic management
haemodynamic alterations 219–21, 220
sequential organ failure assessment (SOFA) score 228
severe sepsis
haemodynamic alterations 219–21, 220
haemodynamic management 221–8
infusion 221–4
inotropic agents 226–7
vasopressor agents 224–6, 225
ventilation 221
resuscitation endpoints 228–9, 229
sevoflurane 175
shock 1–17
aetiology 2, 53
distributive 2, 52
high output states 7–10
anaphylactic shock 10
neurogenic shock 10
sepsis 7–10, 8, 9
low output states 2–7
cardiogenic shock 6, 52
hypovolaemic shock 3–6, 4, 52
obstructive shock 6–7
organ failure 10–17
SHOCK trial 258, 259, 265, 267, 268
Shoemaker criteria 154–5, 155, 159
Signs of Life 24
sildenafil 115
post-transplantation 284
pulmonary hypertension 377
sinoatrial node 102
sinus bradycardia 307
sinus venous defect 182, 293, 295
sitaxsentan 377–8
sodium nitroprusside 112
hypertensive emergencies 418, 419–20
pulmonary hypertension 377
sotalol 131
Spencer, Geoffrey 456
salsalate 107
Saline versus Albumin Fluid Evaluation (SAFE) 222
Sarnoff, Stanley 458
Schafer, Peter Sharpay 454
selectins 13
Senning procedure 172, 292
sepsis 7–10, 8, 9
blood lactate levels 229
categorisation of 219
clinical picture 9
diagnostic criteria 8, 219
echocardiography 69
epidemiology 7–8
haemodynamic management 218–30
management 9–10
pathophysiology 8–9, 9
severe see severe sepsis
septic shock 8
haemodynamic alterations 219–21, 220
sequential organ failure assessment (SOFA) score 228
severe sepsis
haemodynamic alterations 219–21, 220
haemodynamic management 221–8
infusion 221–4
inotropic agents 226–7
vasopressor agents 224–6, 225
ventilation 221
resuscitation endpoints 228–9, 229
sevoflurane 175
shock 1–17
aetiology 2, 53
distributive 2, 52
high output states 7–10
anaphylactic shock 10
neurogenic shock 10
sepsis 7–10, 8, 9
low output states 2–7
cardiogenic shock 6, 52
hypovolaemic shock 3–6, 4, 52
obstructive shock 6–7
organ failure 10–17
SHOCK trial 258, 259, 265, 267, 268
Shoemaker criteria 154–5, 155, 159
Signs of Life 24
sildenafil 115
post-transplantation 284
pulmonary hypertension 377
sinoatrial node 102
sinus bradycardia 307
sinus venous defect 182, 293, 295
sitaxsentan 377–8
sodium nitroprusside 112
hypertensive emergencies 418, 419–20
pulmonary hypertension 377
sotalol 131
Spencer, Geoffrey 456
salsalate 107
Saline versus Albumin Fluid Evaluation (SAFE) 222
Sarnoff, Stanley 458
Schafer, Peter Sharpay 454
selectins 13
Senning procedure 172, 292
sepsis 7–10, 8, 9
blood lactate levels 229
categorisation of 219
clinical picture 9
diagnostic criteria 8, 219
echocardiography 69
epidemiology 7–8
haemodynamic management 218–30
management 9–10
pathophysiology 8–9, 9
severe see severe sepsis
septic shock 8
haemodynamic alterations 219–21, 220
sequential organ failure assessment (SOFA) score 228
severe sepsis
haemodynamic alterations 219–21, 220
haemodynamic management 221–8
infusion 221–4
inotropic agents 226–7
vasopressor agents 224–6, 225
ventilation 221
resuscitation endpoints 228–9, 229
sevoflurane 175
shock 1–17
aetiology 2, 53
distributive 2, 52
high output states 7–10
anaphylactic shock 10
neurogenic shock 10
sepsis 7–10, 8, 9
low output states 2–7
cardiogenic shock 6, 52
hypovolaemic shock 3–6, 4, 52
obstructive shock 6–7
organ failure 10–17
SHOCK trial 258, 259, 265, 267, 268
Shoemaker criteria 154–5, 155, 159
Signs of Life 24
sildenafil 115
post-transplantation 284
pulmonary hypertension 377
sinoatrial node 102
sinus bradycardia 307
sinus venous defect 182, 293, 295
sitaxsentan 377–8
sodium nitroprusside 112
hypertensive emergencies 418, 419–20
pulmonary hypertension 377
sotalol 131
Spencer, Geoffrey 456
spinal cord injury 208
spironolactone, cardiogenic shock 258
splanchnic ischaemia 207–8
Staphylococcus aureus endocarditis 349, 352, 355, 358
Starling curves 458
ST segment elevation myocardial infarction (STEMI)
definition 236
management 239–41
adjunctive and later drug therapy 241
initial therapy 239–40
reperfusion 240–1, 240
stenal wound complications 210
Streptococcus pneumoniae 349
Streptococcus viridans 349
streptokinase 206
adverse reactions 246
stress-induced hyperglycaemia 444–5
stroke, and endocarditis 357
stroke volume 101, 462
maximisation of 159
stroke work 459, 460
sub-aortic stenosis 295
intensive care unit admissions 182
supraventricular tachycardia 304–5, 307
catheter ablation 310
surgery
aortic dissection 392–5
anaesthetic management 394–5
type A 392–3, 393
type B 393–4
coronary artery bypass, arrhythmias 122
endocarditis 360–1, 360
high-risk patients 154–63
identification of 154–7, 155, 156
interventions 157–62
risk of mortality 135
hypertension complicating 416–17, 417
mechanical support after 143, 144
pharmacoprophylaxis 129–31
post-operative bleeding 87
pulmonary hypertension 378–9, 379
thoracic, arrhythmias 123
valve replacement
aortic valve 341–3
pulmonary valve 295
SURVIVE trial 271
sympathetic nervous system 102
syncope, aortic dissection 388
systemic inflammatory response
syndrome 7
arrhythmia risk 123
echocardiography 69
systemic insulin resistance syndrome 443
systemic vascular resistance 101
septic shock 220
systemic-pulmonary shunts
anaesthesia 178
intensive care unit admissions 187–8
tachycardia
adult congenital heart disease 304–6, 306, 308–9
acute treatment 306–9, 307
recognition of 304–6, 306
supraventricular 304–5, 307
catheter ablation 310
ventricular 307
TACTICS trial 265, 265
tadalafil 115
Takayasu’s disease 437, 439
Takotsubo cardiomyopathy 262
tension pneumothorax 7, 29
telipressin, severe sepsis 227
theophylline (aminophylline) 31
thoracic surgery, arrhythmias 123
thoracotomy, emergency 407
thrombocytopenia
causes 90
heparin-induced 89–91
thromboelastography 93, 93
thromboembolic disease, and pulmonary hypertension 372
thromboembolism, mechanical assist devices 147
thrombolysis 31
in pregnancy 427
Thrombolysis In Myocardial Infarction (TIMI) risk score 238
thromboprophylaxis 88
thrombosis
pregnancy 425–6
pulmonary hypertension 370
thromboxane A2 14
thyroid crisis (‘storm’) 450
thyroid dysfunction 76–7, 447–50, 448
hypo- and myxoedema coma 449
thyroid crisis (‘storm’) 450
thyroxine 76–7
tight pericardium 200, 323
tissue factor 15
tissue factor pathway inhibitor 15
toll-like receptors 8–9
torsades de pointes 31, 308
total cavopulmonary connection 292
toxins 29
tranexamic acid 95–6
trans-oesophageal echocardiography 177
  aortic dissection 389–90, 390
  aortic injury 406
  aortic regurgitation 338, 339, 340
  aortic valve disease 330, 331
  infective endocarditis 353, 355
  left ventricular hypertrophy 332
  mitral regurgitation 317, 319
  pericardial effusion 198
  trans-thoracic echocardiography 70
  aortic dissection 389
  cardiac trauma 404
  endocarditis 353
  transforming growth factor-beta 12
  Transfusion Requirements in Critical Care (TRICC) 84
transfusion-related acute lung injury (TRALI) 86
transposition of great arteries 172, 172, 187
  congenitally corrected 172, 298
  intensive care unit admissions 182, 187
tri-iodothyronine 76–7
  cardiac donors 283
tricuspid regurgitation 325
tricuspid valve, Ebstein’s anomaly 172, 186, 297, 297
  troponins 76, 244
  aortic dissection 389
  blunt cardiac injury 404
  tumour necrosis factor, septic shock 221
  tumour necrosis factor-alpha 12
ultrasound 67–70, 69, 70
  intravascular, aortic dissection 391–2
  lung 70
  univentricular heart 173–4, 173, 174
urodilatin 203
urokinase 206
  Valsalva’s manoeuvre 460, 461
valvular heart disease, and cardiogenic shock 257
valvulitis 436
vancomycin 286
  vaptans, cardiogenic shock 258
  vardenafil 115
vascular cell adhesion molecule (VCAM-1) 13
vascular endothelium 103
vascular impedance 102
vascular remodelling 370
vascular smooth muscle 104
vasculitis 434–41
  aorta 435
  Behçet’s disease 436, 437, 438
  Churg-Strauss disease 437, 438
  clinical features 437
  coronary arteries 435
  general features 436
  giant-cell arteritis 436, 437
  investigations 438
  Kawasaki’s disease 437, 439
  myocardium 436
  pericardium 435
  polyarteritis nodosum 437, 438
  relapsing polychondritis 439
  rheumatoid 439
  Takayasu’s disease 437, 439
  treatment 439–40
  valves 436
  Wegener’s granulomatosis 439
  vasoconstriction 369–70
  post-transplantation 284
  pulmonary 114–15
  pulmonary hypertension 376–7
  vasoplegia 447
  vasopressin 30, 111
  severe sepsis 227
  vasopressors 30
  cardiogenic shock 270–2
  severe sepsis 224–6, 225
vegetation see endocarditis
venous anastomosis 173
venous compliance 459
ventilation
  cardiogenic shock 272
  severe sepsis 221
ventricular arrhythmias
  fibrillation 27–9, 28
  incidence 121
  morbidity 124
  tachycardia 27–9, 28
ventricular assist devices 65
ventricular compliance 102
ventricular dysfunction, and revascularisation 248
ventricular fibrillation, adult congenital heart disease 307
ventricular septal defect 295
intensive care unit admissions 182
post-infarct 246
ventricular tachycardia 307
verapamil, hypertensive emergencies 419
volume challenge 53–4
volume depletion 246
Volume Substitution and Insulin Therapy in Severe Sepsis (VISEP) trial 445
Waldron, Barry 457
Wegener’s granulomatosis 439